The Pathophysiology of Peripheral Arterial Disease: Rational Targets for Drug Intervention

The most common cause of peripheral arterial disease (PAD) is atherosclerosis, which begins with an alteration in endothelial biology due to hypercholesterolemia, diabetes mellitus, hypertension, tobacco use, elevated levels of lipoprotein(a) or homocystinemia. With chronic and severe arterial disease, changes begin to occur in the microcirculation, including obstruction at the microvascular level and tissue injury. Based on insights into the vascular biology of PAD, new therapies have been developed and are at various stages of clinical trials. Future pharmacotherapy for PAD will include agents that have one or more of the following attributes: (1) reduce, or even reverse, the progression of atherosclerosis; (2) inhibit plaque rupture; (3) inhibit thrombosis by a novel mechanism; (4) induce angiogenesis; (5) reverse microvascular derangements; (6) affect blood rheology; and (7) enhance skeletal muscle's ability to use available nutrients.

[1]  S. Moore,et al.  Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.

[2]  W. Erl,et al.  Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[3]  K. Hajjar,et al.  The role of lipoprotein(a) in atherogenesis and thrombosis. , 1996, Annual review of medicine.

[4]  S. Bode-Böger,et al.  The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. , 1996, Atherosclerosis.

[5]  D. Harrison,et al.  Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. , 1987, The Journal of clinical investigation.

[6]  R. Alexander,et al.  Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. , 1993, The Journal of clinical investigation.

[7]  K. Okumura,et al.  Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[8]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[9]  P. Tsao,et al.  Nitric oxide regulates monocyte chemotactic protein-1. , 1997, Circulation.

[10]  Geoffrey Burnstock,et al.  Roles of P2‐Purinoceptors in the Cardiovascular System , 1991, Circulation.

[11]  P. Ganz,et al.  Early evidence of endothelial vasodilator dysfunction at coronary branch points. , 1990, Circulation.

[12]  R. Ogilvie,et al.  Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. , 1996, Circulation research.

[13]  R. Busse,et al.  Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. , 1995, Circulation research.

[14]  S. Bode-Böger,et al.  Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. , 1996, Biochemical and biophysical research communications.

[15]  R. Lawn,et al.  Vascular interactions of lipoprotein (a). , 1994, Current opinion in lipidology.

[16]  R. Ross,et al.  The pathogenesis of atherosclerosis (first of two parts). , 1976, The New England journal of medicine.

[17]  P. Tsao,et al.  Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. , 1996, Circulation.

[18]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[19]  P. Tsao,et al.  Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. , 1992, The Journal of clinical investigation.

[20]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[21]  D. Tsikas,et al.  L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. , 1996, Circulation.

[22]  P. Tsao,et al.  Regression or progression. Dependency on vascular nitric oxide. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[23]  V. Maher,et al.  Lipoprotein (a) and coronary heart disease. , 1995, Current opinion in lipidology.

[24]  J. Albers,et al.  Lipid Lowering and Plaque Regression New Insights Into Prevention of Plaque Disruption and Clinical Events in Coronary Disease , 1993, Circulation.

[25]  K. Robinson,et al.  Homocysteine and coronary atherosclerosis. , 1996, Journal of the American College of Cardiology.

[26]  M. Cybulsky,et al.  Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.

[27]  E. Brogi,et al.  Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. , 1994, The Journal of clinical investigation.

[28]  R. Cohen,et al.  Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.